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THE EFFECTS OF THE PART D DOUGHNUT HOLE ON MEDICARE
PATIENTS WHO REQUIRE HIGH-COST MEDICATIONS
Esposito D1, Colby M2, Ball DE3, Garavaglia SB4, Meadows E3, Marciniak MD3
1Mathematica Policy Research, Inc, Princeton, NJ, USA, 2Mathematica Policy Research, Inc, 
Washington, DC, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Medco Health
Solutions, Inc., Franklin Lakes, NJ, USA
OBJECTIVES: To examine the effects of the Medicare Part D doughnut hole on
patients who require treatment with high-cost medications. METHODS: Using 2007
pharmacy claims from Medco Health Solutions, Inc., we used logistic regression 
analysis to examine the likelihood that patients’ spending reached the doughnut hole
($2400) or catastrophic coverage ($5451), or total drug spending equivalents, for
beneﬁ ciaries (enrolled for at least 6 months) with claims for cancer (N  32,625), 
osteoporosis (N  331,337), or rheumatoid arthritis (RA; N  5,712) medications. A 
comparison group with other chronic conditions (N  368,784) was matched to the
study population by age, gender, geography, chronic disease score, and low-income
subsidy (LIS) eligibility. Explanatory variables included plan type, coverage gap expo-
sure, disease type, and demographic characteristics. RESULTS: Compared to patients
with other chronic conditions (55%), patients with cancer (79%), RA (92%), or 
osteoporosis (58%) had higher odds of reaching the doughnut hole compared to 
patients with other chronic conditions (Odds Ratios [OR]  19.3, 32.1, and 2.1,
respectively, p  0.01 for all). A similar pattern of increased odds was observed for
reaching catastrophic coverage (OR cancer  5.2, RA  34.5, osteoporosis  1.4, p 
0.01). Compared with standard prescription drug plan (PDP) enrollees, enhanced PDP
enrollees were more (OR  1.1, p  0.01), Medicare Advantage enrollees were less 
(OR  0.8, p  0.01), and Retiree Drug Subsidy beneﬁ ciaries were as likely (OR 
0.99, p  0.88) to reach the doughnut hole. Relative to enrollees without a coverage 
gap, beneﬁ ciaries with one were less likely to reach $2400 in spending (OR  0.87, 
p  0.01); but were more likely to reach catastrophic coverage (OR  3.0, p  0.01). 
CONCLUSIONS: Regardless of drug plan, the vast majority of Medicare beneﬁ ciaries
in this study with cancer and RA, and most beneﬁ ciaries with osteoporosis faced large
out of pocket drug costs. For beneﬁ ciaries with these conditions, available prescription
coverage may not provide adequate protection from severe ﬁ nancial strain.
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RHEUMATOLOGIST INVOLVEMENT IN CARE OF PATIENTS WITH 
RHEUMATOID ARTHRITIS
Trivedi DN, Kreilick C, Rosenblatt LC
Bristol-Myers Squibb, Plainsboro, NJ, USA
OBJECTIVES: To determine physician specialties involved in rheumatoid arthritis 
(RA) diagnosis and follow-up care. METHODS: A retrospective analysis was per-
formed using PharMetrics” claims database. Patients newly diagnosed with RA (no
RA diagnosis claim in prior 12 months) were identiﬁ ed from April 1, 2005, to June
30, 2006, and were followed for 1 year. Patients were required to have at least one
additional RA diagnosis claim during the follow-up period and had to be continuously 
eligible 12 months before and after initial diagnosis date. Outcomes of interest were 
a) specialty of diagnosing physician b) percentage of patients receiving follow-up care
by a rheumatologist versus other specialties. RESULTS: Of newly diagnosed RA
patients (N  13,633), 34% were diagnosed by a rheumatologist, 13% by general/
family practice (GP), 13% by internal medicine (IM), and 30% by other specialties 
(11% were unknown). Of those diagnosed by a rheumatologist, 94% continued 
receiving rheumatologist care. Of those diagnosed by a GP, 57% continued to receive
care from GP and 13% received care from other specialty; of those diagnosed by IM,
65% continued to receive care from IM and 8% received care from other specialty.
Approximately 26% of those diagnosed by GP or IM received follow-up care from a 
rheumatologist. Irrespective of diagnosing physician specialty, the majority of patients
(52%) were not followed up by a rheumatologist. CONCLUSIONS: This study dem-
onstrates that the majority of RA patients are not diagnosed or followed by a rheu-
matologist. Future studies need to assess whether conﬁ rmation of RA diagnosis and 
follow-up by a rheumatologist, who has extensive training and experience in autoim-
mune disease, has an impact on patient outcomes.
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PHARMACY REFILL PATTERNS FOR SUBCUTANEOUS ANTI-TUMOR
NECROSIS FACTOR AGENTS USED IN THE TREATMENT OF
RHEUMATOID ARTHRITIS IN A MANAGED CARE SETTING
Carter C1, Tang B1, Changolkar A2, McKenzie RS1, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2SOAL PharmaTech Solutions, 
LLC, Philadelphia, PA, USA
OBJECTIVES: To examine pharmacy reﬁ ll patterns of etanercept (ETA) and adalim-
umab (ADA) in the treatment of rheumatoid arthritis (RA) in a managed care popula-
tion. METHODS: Medical and pharmacy claims (January 1, 2000–December 31, 
2006) from a large managed care database were evaluated. Claims for all patients 
aged q18 years meeting the following criteria were included: qtwo diagnosis codes for
RA, no pharmacy or medical history of any biologic use for 6 months prior to anti-
TNF agent index date, anti-TNF agent index date occurring on or after the ﬁ rst RA 
diagnosis date, and q365 persistence days. Patients were excluded if they had a diag-
nosis of ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease, or ulcer-
ative colitis at anytime. Reﬁ ll patterns were examined by calculating the mean time 
(days) between each pharmacy reﬁ ll using NDC codes (actual reﬁ ll days) compared
to the mean days supplied on the claims (recommended reﬁ ll days). Results were 
reported for the ﬁ rst year following anti-TNF agent initiation. RESULTS: A total of 
1239 RA patients newly starting an anti-TNF agent were included (ETA  902, ADA 
 337). ETA patients were slightly younger than ADA patients (ETA  48.8 years, 
ADA  49.2 years, p  0.0001). There was no signiﬁ cant gender difference between
the two groups (ETA  77% female, ADA  75% female, p  0.29). Mean recom-
mended days supplied were 32 and 34 days for ETA and ADA, respectively. Mean
days between actual ETA pharmacy reﬁ lls were longer than recommended for 30%
of the reﬁ ll periods. Mean days between actual ADA pharmacy reﬁ lls were longer than
recommended for 28% of the reﬁ ll periods. CONCLUSIONS: Approximately one-
third of the actual pharmacy ﬁ lls for ETA and ADA had a longer time to patient reﬁ ll
compared to the recommended days supply, which may indicate noncompliance.
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PRIMARY CARE VISITS IN RHEUMATOID ARTHRITIS PATIENTS
RECEIVING INTRAVENOUS VERSUS SUBCUTAENOUS BIOLOGICS: A
RETROSPECTIVE CLAIMS DATABASE STUDY
Rosenblatt LC, Oza D
Bristol-Myers Squibb, Plainsboro, NJ, USA
OBJECTIVES: To determine whether patients diagnosed with rheumatoid arthritis
(RA) receiving intravenous (IV) biologics are more likely to visit a primary care physi-
cian (PCP) than patients receiving subcutaneous (SC) biologics for their RA treatment.
METHODS: A retrospective claims analysis was performed using PharMetrics Patient-
Centric Database. RA patients receiving biologic therapy were identiﬁ ed from January 
2003 to December 2006 and followed for at least 12 months after their ﬁ rst prescrip-
tion for IV or SC biologic (deﬁ ned as index date). Logistic regression analysis predict-
ing PCP visits was conducted, controlling for covariates, such as age, gender, region, 
payer type, provider type, Charlson Comorbidity Index, and speciﬁ c RA-related
comorbidities found to be signiﬁ cant in univariate analysis. RESULTS: There were 
1289 IV and 2543 SC patients included in the study. There were 73% females in the 
IV group vs. 71% in the SC group. Mean age was 58 years in the IV group and 53
years in SC group. The odds of having a PCP visit during follow-up period were 1.22
(95% CI-1.03, 1.44) times higher in the IV group as compared to the SC group, when
controlling for covariates such as age and comorbidities. CONCLUSIONS: RA
patients receiving IV biologics are more likely to maintain PCP visits compared to
patients receiving SC biologics. Future study needs to determine if more frequent
interaction with the health care system can lead to better general health care and the
likelihood of receiving holistic care in patients receiving IV biologics.
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FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS’ DISEASE
MANAGEMENT
Nasonov E1, Le Lay K2, Soldatov D3, Taieb C2
1Rheumatology Institute-Russian Federation, Moscou, Russia, 2Pierre Fabre, Boulogne, France, 
3Pierre Fabre Laboratories, Moscou, Russia
OBJECTIVES: Fibromyalgia syndrome (FMS) is an under-diagnosed disorder, of 
unknown etiology, which affects over 5% of patients in general medical practice; to 
describe Russian rheumatologists’ disease management of ﬁ bromyalgia patients. 
METHODS: The questionnaire was sent to a random sample of Russian practitioners, 
who were answering the same questionnaire as that used by French practitioners in
2003. RESULTS: Seventy-seven of the practitioners claimed that they prescribed a
medical treatment to their patients suffering from ﬁ bromyalgia: 40% prescribed anta-
lgics, 40% prescribed tricyclic antidepressants, 29% serotoninergic anti-depressants, 
30% hypnotics/sedatives, 8 % homeopathic treatments and a little over 1% morphine 
derivatives. 67% claimed that they prescribed extra treatments for their patients 
suffering from ﬁ bromyalgia: 23% prescribed antalgics, 20% prescribed tricyclic
antidepressants, 17% serotoninergic antidepressants, 24% hypnotics/sedatives, 
9% homeopathic treatments and less than 1% morphine derivatives. 82.6 % recom-
mended or prescribed other treatments to their ﬁ bromyalgic patients, namely: 36%
acupuncture, 56% physiotherapy, 14% hypnotherapy, 36% spa treatment, 3% oste-
opathy and 38% relaxation techniques. 91.8% of the doctors advised regular physical
exercise such as swimming and walking (71.9% and 65.6% respectively), with cycling 
being the activity least often advised, by 12.9% of the doctors. CONCLUSIONS:
Treatment for ﬁ bromyalgia must be multidisciplinary and multifactorial, its main 
objective being relieving the patient of their symptoms and allowing them to return 
to their professional and leisure activities – to which treatment of the condition by 
Russian practitioners is a testimony.
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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META-ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF
MODERATE TO SEVERE PSORIASIS
Hawkins NS1, Huntley A2, Eaton J2
1Oxford Outcomes (UK), Oxford, UK, 2Oxford Outcomes (UK), Oxford, Oxfordshire, UK
OBJECTIVES: To assess the comparative efﬁ cacy of biologics for the treatment of 
moderate to severe psoriasis. METHODS: A systematic literature review was con-
ducted to identify all randomized, controlled trials (until October 2008) evaluating 
the efﬁ cacy of approved biologics (adalimumab, efalizumab, etanercept, and inﬂ ix-
imab) for the treatment of moderate to severe psoriasis. As regulatory approval of 
ustekinumab in this indication is anticipated shortly, three Phase 3 trials of ustekinumab 
were also included in this review. A network meta-analysis (NMA) conducted on 
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the ordered probit scale was conducted to evaluate the comparative efﬁ cacy of 
the biologics based on the Psoriasis Area and Severity Index (PASI) responder end-
points. The absolute probability of PASI 50, 75 and 90 responses were estimated. 
RESULTS: A total of 20 studies enrolling 10,108 psoriasis patients, including 1 head-
to-head trial of etanercept and ustekinumab, were identiﬁ ed and included in the NMA.
Thirteen studies evaluated TNF-alpha inhibitors (adalimumab  3, etanercept  6, 
inﬂ iximab  4), 5 studies evaluated T-cell modulators (efalizumab  5), and 3 studies 
evaluated ustekinumab. Baseline patient characteristics were comparable across the
trials. The estimated mean PASI 75 responses were as follows: inﬂ iximab (mean 80%;
95% CI 70–87%), ustekinumab 90 mg (74%; 68–80%), ustekinumab 45 mg (69%; 
62–75%), adalimumab (58%; 49–68%), etanercept 50 mg biw (52%; 45–59%), 
etanercept 25 mg biw (39%; 30–48%), efalizumab (26%; 21–32%), and supportive 
care/placebo (4%; 3–4%). CONCLUSIONS: Based on this analysis, all of the active 
treatments produced a greater response rate than placebo. Ustekinumab and inﬂ ix-
imab had the highest mean response rates followed in order by adalimumab, etaner-
cept and efalizumab. However, there was considerable overlap in the 95% conﬁ dence
intervals.
PSS2
DISTRIBUTION OF PATHOGENS ASSOCIATED WITH ACUTE OTITIS
MEDIA: A SYSTEMATIC REVIEW OF THE LITERATURE
Pereira JA, Ismaila AS, Robson RC, Simpson SD
GlaxoSmithKline, Mississauga, ON, Canada
OBJECTIVES: Acute otitis media (AOM) is a common childhood condition with viral
and bacterial causation. Routine immunization programs currently include 7-valent 
Pneumococcal Conjugate Vaccine (PCV-7), associated with AOM reduction caused by 
Streptococcus pneumoniae only. The study objective was to conduct a systematic lit-
erature review to identify current microbiological picture associated with AOM. 
METHODS: OVID (Medline, Current Content and International Pharmaceutical
Abstract databases), EMBASE, Google and Google Scholar engines were searched with
the following combination of key-words: “acute otitis media”, “bacteria$” and
“vir$”. Eligible articles were in English, published between 1995 and 2008, and 
described studies of pediatric AOM patients with cultures for bacterial and viral iso-
lates. RESULTS: Of the 398 articles screened, 24 separate studies were included (range
 25–623 subjects). Based on a ﬁ xed-effects meta-analysis across all studies, pathogens
isolated were more frequently bacterial (74%) than viral (19%). Compared with the 
15 international studies, U.S. studies recorded a similar isolation rate for bacterial
(73% vs. 74%) and higher isolation rate for viral pathogens (23% vs. 17%). Twenty-
three studies included data on the speciﬁ c bacterial pathogens cultured. Based on a 
ﬁ xed-effects meta-analysis of patients in these studies, S. pneumoniae and Haemophi-
lus inﬂ uenzae were isolated with similar frequency (35% vs. 36%) and Moraxella
catarrhalis at 6%. Slightly higher isolation rates of M. catarrhalis (10%) and lower 
rates of H. inﬂ uenzae (31%) were observed in U.S. patients, compared with interna-
tional patients. CONCLUSIONS: Bacterial pathogens are frequently associated with
AOM in pediatric populations worldwide and were isolated 3-times more often than 
viral pathogens. S. pneumoniae and H. inﬂ uenzae are the bacterial pathogens most
commonly isolated in AOM cases, with nearly equal frequency. A vaccine that 
addresses more than one cause of AOM would be expected to greatly reduce the 
clinical and economic burden associated with this common condition.
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USING “NUMBER NEEDED TO TREAT” TO HELP CONCEPTUALIZE
THE MAGNITUDE OF BENEFIT AND RISK OF TNFÁ INHIBITORS
FOR PATIENTS WITH SEVERE PSORIASIS
Warner J1, Bhosle MJ2, Balkrishnan R2, Yentzer BA3, Feldman SR4
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Ohio State University, 
Columbus, OH, USA, 3Wake Forest University School of Medicine, Winston-Salem, NC, USA, 
4Wake Forest University School of Medicine, Winston Salem, NC, USA
OBJECTIVES: Risks and beneﬁ ts of TNF-alpha inhibitors are often presented using 
statistical descriptions that are difﬁ cult to directly translate for patients into a clini-
cally-meaningful context. The objective of this study was to illustrate the risks and 
beneﬁ ts of TNF-alpha inhibitors in relation to risks that patients understand. 
METHODS: We performed a number needed to treat analysis for psoriasis patients 
on TNFalpha inhibitors via a Medline and Embase search. We determined the number
needed to beneﬁ t and the number needed to harm with TNF-alpha inhibitor treatment. 
We compared the risk of serious adverse events (SAE) from treatment with a TNF-
alpha inhibitor to the risk of death from driving a car. The risk analyses were limited
to tuberculosis, lymphoma, and demyelinating disease. RESULTS: The numbers
needed to beneﬁ t were 2.1 for etanercept, 1.4 for inﬂ iximab, and 1.6 for adalimumab.
Depending on adverse event, the numbers needed to harm ranged from 380 to 360,000 
treated patients per year. Screening prior to the initiation of TNF-alpha inhibitor 
therapy reduces risk of tuberculosis. Patients are about as likely to die in a car accident
as have a serious adverse event from TNF-alpha inhibitor treatment. CONCLU-
SIONS: All 3 of the TNF-alpha antagonists have remarkable efﬁ cacy in patients with 
severe psoriasis. The risks of serious adverse events are relatively rare and comparable 
to risks patients take on a regular basis such as driving a car. For severe psoriasis, the 
beneﬁ ts of TNF-alpha inhibitors may greatly outweigh the risks for many patients.
SENSORY SYSTEMS DISORDERS – Cost Studies
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A COST COMPARISON OF ADALIMUMAB AND ETANERCEPT FOR THE 
TREATMENT OF CHRONIC PLAQUE PSORIASIS IN THE UNITED
KINGDOM
Lebmeier M1, Conway P2, Warburton J1
1Wyeth Pharmaceuticals, Maidenhead, UK, 2Wyeth Europa, Berkshire, UK
OBJECTIVES: To assess the cost differences between adalimumab and etanercept for
chronic plaque psoriasis. METHODS: A model was constructed to compare the drug
acquisition costs for adalimumab and etanercept for chronic plaque psoriasis for a
hypothetical primary care trust. The number of patients eligible for anti-TNF treat-
ment was taken from published sources. Patients were assumed to receive either etan-
ercept intermittently, mixed intermittent and continuous, continuous, or continuous 
adalimumab. Market research demonstrated that about 36% of patients are likely to 
receive continuous etanercept. Adalimumab, in contrast can not be used intermittently. 
Costs were estimated from a UK payer perspective. The time horizon is three years.
RESULTS: We estimated that the hypothetical PCT would cover 250,000 people, 
which is approximately the average size of a PCT in the UK. Of these 195,000 would 
be q 18 years of age. thirty-ﬁ ve patients would meet the criteria for either adalimumab
or etanercept. Providing that all patients would receive intermittent etanercept this 
would cost the NHS GBP 722,190, if 36% receive continuous etanercept and the rest 
intermittent etanercept it would cost GBP 816,453, whilst if all patients would receive 
continuous etanercept it would cost GBP 975,975. All patients receiving continuous 
adalimumab would cost GBP 1,001,000. CONCLUSIONS: Our model found poten-
tial for cost savings for PCTs from using etanercept instead of adalimumab, within 
the recommended patient groups for chronic plaque psoriasis. Savings will be increas-
ingly important if the proportion of eligible patients who receive treatment increases 
from the current level.
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AN ECONOMIC ANALYSIS TO EVALUATE ANTI-GLAUCOMA
PHARMACOTHERAPY
Bhowmik D, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: To compare the use of prostaglandin analogues namely, Bimatoprost,
Travoprost and Latanoprost, in the treatment of glaucoma by conducting a cost 
effectiveness analysis considering medication related adverse event and patient-
persistence as indirect costs. METHODS: The study was conducted from a third-
party payer’s (Medicare) perspective with a time-frame of 12 months. Literature 
review was conducted to estimate medical-visit costs, average reduction in intra-ocular
pressure (IOP) in mm Hg, medications related adverse event and patient-persistence
to the pharmacotherapy. Average wholesale price (AWP) for the drug considered
(obtained from the REDBOOK-2007), mean number of drops per bottle (according 
to the best instillation method), days per bottle, and annual usage of bottles for these 
drugs were also obtained from published literature to determine the annual cost
associated with prostaglandin pharmacotherapy. DATA (version 3.0) software package 
was used to perform the decision analysis. Incremental cost-effectiveness ratios (ICER)
were calculated using intra-ocular-pressure reduction as efﬁ cacy estimate. Sensitivity 
analyses were conducted by changing the cost information by 25% to account for the 
variation in drug administration. A discounting rate of 5% was used to project all 
cost estimates to year 2008. RESULTS: The decision-analysis indicated Travoprost 
to be slightly inexpensive among the three prostaglandins (expected value $616.33),
followed by Bimatoprost (expected value $618.73) and Latanoprost (expected 
value $626.29). Compared with Latanoprost, Travoprost and Bimatoprost provided
a higher IOP-reduction with ICER of $(9.96) and $(7.56) respectively. Results
of sensitivity analyses were robust to the decision analysis performed. CONCLU-
SIONS: Based on our analysis Travoprost and Bimatoprost was more cost-effective 
than Latanoprost. Health care decision-makers should consider the effect of adverse 
drug events and persistency proﬁ les on the direct medical costs to prioritize the pros-
taglandin analogues for long-term treatment of glaucoma. Further, analyses using 
adherence data for speciﬁ c patient groups can provide valuable information to decision
makers.
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A PHARMACOECONOMIC APPROACH OF THE USE OF
INTRAVENOUS ANTIBIOTIC THERAPY FOR COMPLICATED SKIN
AND SKIN-STRUCTURE INFECTIONS IN PUBLIC HEALTH CARE
INSTITUTIONS IN MEXICO
Soria-Cedillo IF1, Baca-Muro VI2, Martinez-Revelles M3, Jirash J3, De la Mora-Chávez T4, 
Garcia-Contreras F4
1Research Consulting, Hacienda Ojo de Agua, State of Mexico, Mexico, 2Research Consulting, 
Puebla, Puebla, Mexico, 3Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, 
4Instituto Mexicano del Seguro Social, Mexico City, Mexico
OBJECTIVES: To calculate the cost per clinical success (CS) in the antibiotic treatment 
for complicated skin and skin-structure infections (CSSI) in Mexican Social Security
Institutions in Mexico. METHODS: The use of either i.v. Daptomycin (DAP), i.v. 
Vancomycin (VAN) or i.v. Linezolid (LIN) as ﬁ rst-line and second-line antibiotic
therapy was compared in a cost-effectiveness study. Data was collected from a sys-
tematic review which included the most recent published articles measuring clinical
improvement, length of stay at hospital services and adverse events due to the use of 
